Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9123)
All Articles published online
|
Publishing Process of This Article
|
Dec 28, 2015 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554 [PMID: 26730167 DOI: 10.3748/wjg.v21.i48.13548] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i48/13548.htm |
| Number | Citing Articles |
| 1 |
Shoko Ono, Mototsugu Kato, Soichi Nakagawa, Katsuhiro Mabe, Naoya Sakamoto. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017; 22(3) doi: 10.1111/hel.12374
|
| 2 |
James P. Franciosi, Edward B. Mougey, Andre Williams, Roberto A. Gomez‐Suarez, Cameron Thomas, Christa L. Creech, Katherine George, Diana Corao, John J. Lima. Association BetweenCYP2C19*17Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. The Journal of Clinical Pharmacology 2018; 58(1): 89 doi: 10.1002/jcph.977
|
| 3 |
Yoen‐Young Chuah, Deng‐Chyang Wu, Seng‐Kee Chuah, Jyh‐Chin Yang, Tzong‐Hsi Lee, Hong‐Zen Yeh, Chan‐Lin Chen, Yu‐Hwa Liu, Ping‐I Hsu. Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey). Helicobacter 2017; 22(3) doi: 10.1111/hel.12380
|
| 4 |
Muhamad A. K. Shakhatreh, Omar F. Khabour, Karem H. Alzoubi, Mohammed N. BaniHani, Ahmed Abu-Siniyeh, Nabil A. Bashir, Salsabeel H. Sabi, Mahmoud Mahafdah. <p>The Influence of <em>IL-1B</em> Gene Polymorphisms on <em>H. pylori</em> Infection and Triple Treatment Response Among Jordanian Population</p>. The Application of Clinical Genetics 2020; : 139 doi: 10.2147/TACG.S253778
|
| 5 |
Loan Le Thi Thuy, Liem Thanh Nguyen, Hoang Anh Vu, Nghia An Nguyen, Tuan Anh Nguyen. Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam. BMC Pediatrics 2024; 24(1) doi: 10.1186/s12887-024-04581-w
|
| 6 |
Joon Sung Kim, Weonjin Ko, Jun‐Won Chung, Tae Ho Kim. Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study. Helicobacter 2023; 28(3) doi: 10.1111/hel.12977
|
| 7 |
Gwang Ha Kim. Status ofHelicobacter pyloriEradication in Japan. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(1): 4 doi: 10.7704/kjhugr.2017.17.1.4
|
| 8 |
Nihal El Rouby, John J. Lima, Julie A. Johnson. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(4): 447 doi: 10.1080/17425255.2018.1461835
|
| 9 |
Dana M. Harris, Fernando F. Stancampiano, M. Caroline Burton, Ann M. Moyer, Michael J. Schuh, Jose R. Valery, Yan Bi. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice. Digestive Diseases and Sciences 2021; 66(12): 4120 doi: 10.1007/s10620-020-06814-1
|
| 10 |
Kazutake Oguma, Sadanori Kubo, Fumihiko Nozu, Hiroaki Shiraishi, Takeshi Yano, Shigeaki Aihara, Masaaki Matsukawa, Kazuhide Kumagai. A study of digestive symptoms before and after successful Helicobacter pylori eradication therapy. Progress of Digestive Endoscopy 2017; 91(1): 52 doi: 10.11641/pde.91.1_52
|
| 11 |
Paulius Jonaitis, Laimas Jonaitis, Juozas Kupcinskas. Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication Regimens. Current Drug Metabolism 2020; 21(11): 830 doi: 10.2174/1389200221666200514081442
|
| 12 |
Mohammed N. BaniHani, Omar F. Khabour, Karem H. Alzoubi, Nabil A. Bashir, Muhamad Ali K. Shakhatreh, Salsabeel H. Sabi, Nasr Alrabadi. The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians. Genes 2020; 11(1): 63 doi: 10.3390/genes11010063
|
| 13 |
Byeong Yun Ahn, Soo-Jeong Cho. Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 174 doi: 10.7704/kjhugr.2023.0041
|
| 14 |
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng.
The Effect of
CYP2C19
Gene Polymorphism on the Eradication Rate of
Helicobacter Pylori
by Proton Pump Inhibitors-ContAining Regimens in Asian Populations: a Meta-Analysis
. Pharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
|
| 15 |
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Advances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
|
| 16 |
Yuehua Gong, Yuan Yuan. Resistance mechanisms ofHelicobacter pyloriand its dual target precise therapy. Critical Reviews in Microbiology 2018; 44(3): 371 doi: 10.1080/1040841X.2017.1418285
|
| 17 |
|
| 18 |
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy. Journal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
|
| 19 |
Komei Iwai, Tetsuji Azuma, Takatoshi Yonenaga, Yasuyuki Sasai, Kazutoshi Watanabe, Akihiro Obora, Fumiko Deguchi, Takao Kojima, Takaaki Tomofuji. Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adults. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54757-8
|
| 20 |
Kazutake Oguma, Masashi Sato, Sadanori Kubo, Hiroaki Shiraish, Takeshi Yano, Shigeaki Aihara, Masaaki Matsukawa, Kazuhide Kumagai. A study of symptoms, eradication rates, and the degree of atrophy in patients with Helicobacter pylori-associated gastritis. Progress of Digestive Endoscopy 2018; 92(1): 50 doi: 10.11641/pde.92.1_50
|
| 21 |
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
|
| 22 |
Hyeonsoo Park, Choon Ok Kim, Mikyung Kim, Yeji Lim, Woo Yul Lee, Sukyong Yoon, Min Soo Park. Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Translational and Clinical Pharmacology 2020; 28(3): 136 doi: 10.12793/tcp.2020.28.e16
|
| 23 |
Na‐Yun Su, Qing Shi, Hao Mei, Jie Hu, Yu‐Xiang Liu, Han‐Ning Liu, Heng‐Qi Liu, Yan Guo, Xing‐wei Wang, Chun‐Hui Lan. Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter 2023; 28(5) doi: 10.1111/hel.13003
|
| 24 |
Yoshimasa Saito, Kaho Konno, Moeka Sato, Masaru Nakano, Yukako Kato, Hidetsugu Saito, Hiroshi Serizawa. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers 2019; 11(1): 116 doi: 10.3390/cancers11010116
|
| 25 |
William D. Chey, Francis Mégraud, Loren Laine, Luis J. López, Barbara J. Hunt, Colin W. Howden. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022; 163(3): 608 doi: 10.1053/j.gastro.2022.05.055
|